# Summit Therapeutics

Source: https://onco.cc/companies/summit-therapeutics/  
OnCo record `summit-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Summit Therapeutics holds Western rights to ivonescimab and is running the global HARMONi trials.

## Summary

Summit Therapeutics, based in Miami and listed as SMMT, holds the Western rights to ivonescimab, Akeso's PD-1 by VEGF bispecific antibody, and is running the global HARMONi trials. HARMONi-3 tests it in first-line non-small-cell lung cancer and HARMONi-7 in PD-L1-high disease, both phase 3, and the company's biologics licence strategy follows the overall survival result of the HARMONi trial. OnCo links it to non-small-cell lung cancer and cutaneous squamous cell carcinoma, to HARMONi-A, and to the HARMONi-2 paper in which ivonescimab beat pembrolizumab head to head. Whether a Chinese head-to-head win can be reproduced in a Western population, and whether the FDA will accept it, is the open question the company exists to answer. Ivonescimab has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Miami, FL
- Type: biotech
- Website: https://www.smmttx.com
- Ticker: SMMT

## Sources

- Official website: https://www.smmttx.com

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- drugs: [Ivonescimab](https://onco.cc/drugs/ivonescimab/)
- trials: [A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07535437/), [A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma](https://onco.cc/trials/nct07815665/), [A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07535463/), [Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1](https://onco.cc/trials/nct06767514/), [HARMONi-3](https://onco.cc/trials/harmoni-3/), [HARMONi-A](https://onco.cc/trials/harmoni-a/), [Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC](https://onco.cc/trials/nct07405190/), [Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer](https://onco.cc/trials/nct06959550/), [Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer](https://onco.cc/trials/nct07057791/), [Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets](https://onco.cc/trials/nct07234877/), [Phase III Study of AK112 for NSCLC Patients](https://onco.cc/trials/nct06396065/), [Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer](https://onco.cc/trials/nct07228832/), [Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases](https://onco.cc/trials/nct07359456/)
- cancers: [Cutaneous squamous cell carcinoma](https://onco.cc/cancers/cutaneous-scc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [PD-L1-high non-small-cell lung cancer without a driver mutation](https://onco.cc/cancers/pdl1-high-nsclc/)
- key papers: [HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer](https://onco.cc/key-papers/paper-harmoni-2-lancet-2025/)

---
JSON: https://onco.cc/api/v1/entities/summit-therapeutics.json